Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ferrari NV (RACE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Ferrari (RACE) trades at $376.64, up 0.53% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.73 exceeding expectations. Revenue grew to $7.15B in 2025, supported by a 22.19% net margin and 41.96% ROE. Recent news highlights include a new EV model launch and ongoing share buybacks, while technical indicators point to support near $372 and resistance at $377.

The outlook remains positive with a consensus price target of $467.50, implying 24% upside. Key risks include execution challenges with new electric vehicles and economic sensitivity. Analyst sentiment is strongly bullish (72% buy ratings), but investors should monitor competitive pressures and margin sustainability amid hybrid transition efforts.